After the trading session on the 9th of January trading in shares of Novelion Therapeutics (NVLNF) will likely be suspended indefinitely. If the company’s liquidation plan is approved by the Court of British Columbia this once sizable drug company will delist. Eventually, it will cease to exist, but not before distributing its remaining assets to its shareholders.
And, after taking into account liquidation cost (which the company has already put aside), those remaining assets will likely not consist of any cash, but of 12.5 million shares in UK-listed Amryt Pharma (LON: AMYT). Amryt is currently